News 2024-09-13
Keep hope alive! We invite you to stay tuned to DMD
From September 6 to 7 2024, the Porton Wecare Program accompanied the families of four Chongqing DMD patients to Shanghai to participate in the 13th China Rare Disease Summit 2024.
The summit, co-sponsored by the Chinese Organization for Rare Disorders (CORD) and Xinhua Hospital affiliated with Shanghai Jiaotong University School of Medicine, was held from September 6 to 8, 2024.
During the summit, we participated in the “Duchenne Muscular Dystrophy (DMD) Academic Seminar” with the families. Medical experts and representatives from biopharmaceutical companies, who have long focused on the diagnosis and treatment of DMD, were invited to share the latest research results and treatment strategies with families of DMD patients from across the country through keynote speeches, round-table forums, and other interactive sessions. The seminar aimed to provide insights into the future development directions of DMD in China, bringing more benefits to the patients.
Through this summit, we have not only witnessed the rapid advancements in the field of DMD research but also the genuine care from various sectors of society towards DMD patients. All hope will come true and it will no longer be a dream.
In the future, the Porton Wecare Program will continue to focus on the DMD, enabling the public's early access to good medicines！
*Photo Source: Live Photos from the 13th China Rare Disease Summit
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
